Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Enrolled participants were randomized to receive 3 mg, 7 mg, or 14 mg of oral semaglutide or placebo once daily for 52 weeks
Timeline & What to Expect Weeks 1-2: You may notice reduced appetite and food cravings within the first few days
By understanding the why behind the appearance of your medication, you can move past the initial uncertainty and focus on the sustainable lifestyle changes that lead to long-term success
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al
10.1002/adhm.202300931 48 GaoC.DaiW.LiuD.WangX.ZhangT.YuB.et al (2025)
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus in adults (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
